Epix Pharmaceuticals, Inc. (EPIX) announced revised results from its Phase 2a clinical trial of PRX-03140, its novel 5-HT4 agonist, in Alzheimer's disease.
The trial was designed to assess the effects of PRX-03140 following two weeks of treatment as monotherapy and separately in combination with donepezil (Aricept) in patients with mild Alzheimer's disease.
The corrected results show that patients receiving 150 mg of PRX-03140 orally once daily as monotherapy achieved a mean 3.6 point improvement on the ADAS-cog versus a 0.9 point worsening in patients on placebo, which continues to be statistically significant (p= 0.021).
Data for the patients on a 50 mg dose of PRX-03140 showed a 1.0 point improvement on the ADAS-cog. The monotherapy dose response (150 mg versus 50 mg versus placebo) continues to be statistically significant with p=0.026.
For comments and feedback: editorial@rttnews.com